Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

COPD

COVID-19

Cardiovascular

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Digital Health

Duchenne Muscular Dystrophy

Employers

Epilepsy

Gastroenterology

Gene Therapy

Heart Failure

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Non-Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Parkinson Disease

Population Health

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Articles

The warning letters issued to 7 manufacturers are part of a larger, ongoing effort by the FDA to address the manufacturing, distribution, and sale of illegal and unauthorized e-cigarettes.

E-Cigarettes Packaged as Youth-Appealing Items Prompt FDA Warning Letters

The Center on Health Equity and Access highlights the most recent updates in the realm of health equity, including news, research findings, and initiatives focused on mitigating health care disparities and enhancing overall access to quality care.

Health Equity and Access Weekly Roundup: December 2, 2023

Jordyn Sava is an assistant editor for Targeted Oncology

Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.

FDA Grants Priority Review to Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

A mandatory nationwide transition from reference adalimumab to a biosimilar was implemented in New Zealand.

Patients With Rheumatic Diseases Report Low Satisfaction After Mandatory Biosimilar Switch

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

James G. Terwilliger, MPH

Articles